1
|
Barrios V, Escobar C, Ortiz Cortés C, Cosín Sales J, Pascual Figal D, García-Moll Marimón X. Management of patients with heart failure treated in cardiology consultations: IC-BERG Study. Rev Clin Esp 2020. [DOI: 10.1016/j.rceng.2019.10.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
2
|
Barrios V, Escobar C, Ortiz Cortés C, Cosín Sales J, Pascual Figal D, García-Moll Marimón X. Manejo de los pacientes con insuficiencia cardiaca atendidos en la consulta de cardiología: Estudio IC-BERG. Rev Clin Esp 2020; 220:339-349. [DOI: 10.1016/j.rce.2019.10.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Revised: 10/30/2019] [Accepted: 10/31/2019] [Indexed: 10/24/2022]
|
3
|
Morillas-Climent H, Seller-Moya J, Vicedo-López Á, Galcerá-Jornet E, Alania-Torres E, Rodríguez-Pichardo Y, Larumbe-Rodríguez A, Valle-Muñoz A. Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice. J Comp Eff Res 2019; 8:685-697. [DOI: 10.2217/cer-2019-0014] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Aim: To analyze the impact of sacubitril/valsartan on functional class, surrogate parameters and clinical outcomes in clinical practice. Methods: Retrospective study of patients with heart failure and reduced ejection fraction that started treatment with sacubitril/valsartan. Results: 149 patients (70.7 ± 9.6 years) were included. At baseline, 83.9, 15.4 and 0.7% were taking sacubitril/valsartan 24/26, 49/51 and 97/103 mg, respectively. After 316.1 ± 155.9 days, these numbers moved to 38.9, 39.6, 12.8% (8.7% discontinued). Sacubitril/valsartan improved functional class (from 2.3 ± 0.6 to 1.8 ± 0.5; p < 0.001), increased ejection fraction (from 31.2 ± 7.0 to 37.3 ± 10.5%; p < 0.001) and reduced NT-proBNP (from 3884 ± 4871 to 1975.3 ± 3006.6 pg/ml; p = 0.0001). Rates of any event, cardiovascular death and heart failure hospitalization/decompensation were 13.2 events/100 patient-years. Conclusion: Sacubitril/valsartan is effective and safe in routine practice.
Collapse
|
4
|
Fernández-Vázquez JP, Fernández-Vázquez F. Atención primaria: El eje de la continuidad asistencial. Semergen 2018; 44:525-526. [DOI: 10.1016/j.semerg.2018.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2018] [Revised: 11/06/2018] [Indexed: 10/27/2022]
|